Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease

@article{Ellison2010ChildhoodMN,
  title={Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease},
  author={David W. Ellison},
  journal={Acta Neuropathologica},
  year={2010},
  volume={120},
  pages={305-316}
}
  • D. Ellison
  • Published 2010
  • Medicine
  • Acta Neuropathologica
Increasing recognition of pediatric medulloblastoma as a heterogeneous disease, with histopathological and molecular variants that have distinct biological behaviors, will impact how the disease is classified and treated. A combination of clinicopathological evaluation and assays based on molecular subgroups of disease will allow stratification of patients into risk groups and a more tailored approach to therapy. Patients with low-risk disease could be treated with de-escalated adjuvant therapy… Expand
Evolving molecular era of childhood medulloblastoma: time to revisit therapy.
TLDR
Improved understanding of the biological, molecular and genetic make-up of these tumors now clearly identifies it as a compendium of four distinct subtypes (WNT, SHH, group 3 and 4), which has resulted in endeavors to profile targeted therapy. Expand
Childhood Medulloblastoma
TLDR
A novel combined histopathological and molecular stratification scheme into 4 subgroups could help to identify patients who might benefit from dose escalation and de-escalation of therapy and bring optimism in treating these patients as scholars now have the ability to profile a more targeted therapy approach. Expand
Medulloblastoma: advances and challenges
TLDR
This work has shown that response to therapy appears to be subtype-specific, and the potential to vastly reduce therapy-mediated toxicity to patients with tumor subtypes that have good outcomes, while improving therapy through targeting for the poor responders, is now palpable. Expand
Medulloblastoma: molecular pathways and histopathological classification
TLDR
This review has tried to bring together molecular pathophysiology of the neoplasm and current pathological classification, thus making an effort to relate tumor biology and the histological picture. Expand
Pediatric medulloblastoma in the molecular era: what are the surgical implications?
TLDR
Using the four main molecular MB subgroups, a restratification into clinicogenomic risk categories quantified an unacceptable survival for the high-risk group, urging researchers to focus their efforts towards acquiring a greater biological understanding of these children. Expand
The tumor biology and molecular characteristics of medulloblastoma identifying prognostic factors associated with survival outcomes and prognosis
Medulloblastomas (MB) are highly aggressive primitive neuroectodermal tumors (PNET) usually located in the posterior fossa. Current treatment for MBs, which includes a combination of surgery,Expand
Medulloblastoma
TLDR
This Primer by Pfister and colleagues reviews the molecular genetics, diagnosis and management of medulloblastoma and touches upon the quality of life of patients and future outlooks. Expand
Signaling pathway and molecular subgroups of medulloblastoma.
  • K. Li, K. Lau, H. Ng
  • Biology, Medicine
  • International journal of clinical and experimental pathology
  • 2013
TLDR
The biological signaling pathways involved in MB pathogenesis are discussed and how identification of molecular subgroups is going to change the authors' routine disease diagnosis and clinical management is discussed. Expand
Medulloblastoma: Molecular understanding, treatment evolution, and new developments.
TLDR
The recent advances and challenges associated with MB classification are highlighted, and the development of therapeutic treatments targeting novel subgroup-specific molecular and epigenetic factors, especially those in the SHH-driven MB tumors are highlighted. Expand
Review and update about medulloblastoma in children
TLDR
Improvements in the understanding of the biological and molecular characteristics of medulloblastoma promise a dramatic change in the accuracy of staging and treatment of this tumor in the near future that are sure to bring about further improvements in survival. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 103 REFERENCES
Molecular Biology of Medulloblastoma: Will It Ever Make a Difference to Clinical Management?
TLDR
It is imperative that the neuro-oncology community give greater priority to studies of medulloblastoma molecular biology: unless this is done, patients will face a bleak future in which there is no accurate disease-risk stratification tool and no effective new treatments. Expand
Pathological and molecular heterogeneity of medulloblastoma
TLDR
Better understanding of the growth control mechanisms involved in the development and progression of medulloblastoma will allow improved therapeutic stratification of patients using existing adjuvant therapy as well as the development of new therapeutic approaches. Expand
What's new in neuro-oncology? Recent advances in medulloblastoma.
TLDR
The current histopathological classification system for medulloblastoma is reviewed and a review of how future efforts in this disease will seek to translate knowledge of disease biology into clinical practice is concluded. Expand
Anaplasia and Grading in Medulloblastomas
TLDR
It is believed anaplastic change represents a type of malignant progression common to many medulloblastoma subtypes and to other CNS embryonal lesions as well, and correlation of these histological changes with the accumulation of genetic events suggests a model for the histological and molecular progression of medullOBlastoma. Expand
Current therapy for medulloblastoma
TLDR
It is envisaged that in the near future children diagnosed with medulloblastoma will be more accurately stratified based on a combination of clinical variables and molecular profiles, which will permit delivery of individualized therapy using conventional treatment modalities in conjunction with novel targeted therapeutic approaches. Expand
Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features
TLDR
The new medulloblastoma classification presented in this study will greatly enhance the understanding of this heterogeneous disease and enable a better selection and evaluation of patients in clinical trials, and it will support the development of new molecular targeted therapies. Expand
Management of and prognosis with medulloblastoma: therapy at a crossroads.
TLDR
A better understanding of the biological characteristics of medulloblastoma including the cell or cells of origin and the aberrant cellular signaling pathways involved has the promise of dramatically changing tumor stratification and treatment in the near future. Expand
Clinical and molecular stratification of disease risk in medulloblastoma
TLDR
The hypothesis that a combination of clinical and molecular factors may afford a more reliable means of assigning disease risk in patients with medulloblastoma is supported, thereby providing a more accurate basis for targeting therapy in children with this disease. Expand
The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials
TLDR
Pan-European clinical trials being planned for medulloblastoma by the SIOP Brain tumour group will assess the stratification of patients using molecular and histological biomarkers, alongside clinical indices, to select favourable, standard and high-risk treatment groups, with the overall aim of maximising survival whilst minimising late effects. Expand
Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients
TLDR
Combined evaluation of novel histopathological features and molecular cytogenetic abnormalities promises to allow stratification of patients with medulloblastoma, such that those likely to be cured will be spared the side effects of maximal therapy, which can be targeted at those with aggressive disease. Expand
...
1
2
3
4
5
...